CONCLUSIONS AND CLINICAL IMPORTANCE: Lapatinib showed efficacy in HER2‐positive metastatic mammary carcinomas, prolonging survival compared with HER2‐negative and IMC cases, with good tolerability. This evidence concerns the gene ERBB2 and breast carcinoma.